



## **Orthofix International Announces Launch of Collage( TM ); Synthetic Bone Graft Substitute**

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International (NASDAQ: OFIX) announces the full market release of Collage™ Osteoconductive Scaffold, a new bone graft substitute, for use in spine and orthopedic indications, at this week's North American Spine Society (NASS) meeting to be held in Chicago, Illinois.

"We are proud to announce the launch of Collage, our new synthetic platform based on highly-purified biocompatible materials of  $\beta$ -TCP and type-1 collagen," said Michael Finegan, President of Biologics. "We have been tremendously successful with Trinity Evolution and can now focus on broadening our portfolio of biologic products so that we can fulfill all the needs of our customers. The synthetic segment of the market is large, attractive, and presents a perfect complement to our existing biologic portfolio."

The U.S. market for synthetic bone graft substitutes is estimated to include more than 320,000 procedures and is valued at approximately \$360 million annually, according to a recent iData Research report.

### **About Orthofix**

Orthofix International N.V. is a global medical device company offering a broad line of minimally invasive surgical, and non-surgical products for the spine, orthopedics, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages helping them achieve a more active and mobile lifestyle. Orthofix's products are widely distributed around the world to orthopedic surgeons and patients via Orthofix's sales representatives and its subsidiaries, including BREG, Inc., and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, Texas Scottish Rite Hospital for Children, and the Cleveland Clinical Foundation. For more information about Orthofix, please visit <http://www.orthofix.com>.

Orthofix International N.V.  
Mark Quick, 214-937-2924  
Director of Investor Relations and Business Development  
[markquick@orthofix.com](mailto:markquick@orthofix.com)

Source: Orthofix International N.V.

News Provided by Acquire Media